false	These agents, including norfloxacin,  <e1> ciprofloxacin </e1> , ofloxacin,  <e2> enoxacin </e2> , and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	These agents, including  <e1> norfloxacin </e1> , ciprofloxacin, ofloxacin, enoxacin, and  <e2> lomefloxacin </e2> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	These agents, including norfloxacin,  <e1> ciprofloxacin </e1> , ofloxacin, enoxacin, and  <e2> lomefloxacin </e2> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	These agents, including  <e1> norfloxacin </e1> , ciprofloxacin, ofloxacin,  <e2> enoxacin </e2> , and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( <e1> ampicillin </e1> , cefazolin,  <e2> oxytetracycline </e2>  and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of  <e1> GL </e1>  with four kinds of  <e2> antibiotics </e2>  (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of  <e1> GL </e1>  with four kinds of antibiotics ( <e2> ampicillin </e2> , cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin,  <e1> cefazolin </e1> ,  <e2> oxytetracycline </e2>  and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of  <e1> antibiotics </e1>  ( <e2> ampicillin </e2> , cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	Differential regulation of tyrosine phosphorylation in tumor cells by  <e1> contortrostatin </e1> , a homodimeric disintegrin, and monomeric disintegrins  <e2> echistatin </e2>  and flavoridin.
false	Exposed histidines on  <e1> toxin A </e1>  are available for  <e2> zinc </e2>  chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.
false	Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for  <e1> toxin A </e1>  using  <e2> zinc </e2> -chelating chromatography.
false	Analysis of the concentration of  <e1> budesonide </e1>  following ultracentrifugation indicated that there is rapid equilibration of budesonide between the  <e2> Survanta </e2>  and aqueous phase. 
false	Note: dissolution of aerosol particles of  <e1> budesonide </e1>  in Survanta, a model  <e2> lung surfactant </e2> .
false	The effect of a  <e1> pulmonary surfactant </e1>  extract from bovine lung,  <e2> Survanta </e2> , on the dissolution rate of aerosol particles of budesonide was determined. 
false	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  <e1> SCH-23390 </e1>  but not by an  <e2> atypical neuroleptic </e2>  clozapine. 
false	Note: dissolution of aerosol particles of budesonide in  <e1> Survanta </e1> , a model  <e2> lung surfactant </e2> .
false	Then, the effects of metabotropic glutamate receptor (mGluR) agonists,  <e1> DCG-IV </e1>  and  <e2> L-CCG-1 </e2> , on the above behavioral changes induced by PCP were found. 
false	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  <e1> PCP </e1> , DCG-IV, and  <e2> L-CCG-1 </e2>  was carried out.
false	In order to examine some molecular mechanisms of  <e1> PCP </e1> -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP,  <e2> DCG-IV </e2> , and L-CCG-1 was carried out.
false	The effects of  <e1> DCG-IV </e1>  and L-CCG-1 upon  <e2> phencyclidine </e2>  (PCP)-induced locomotion and behavioral changes in mice.
false	The effects of DCG-IV and  <e1> L-CCG-1 </e1>  upon phencyclidine ( <e2> PCP </e2> )-induced locomotion and behavioral changes in mice.
false	Like  <e1> ibogaine </e1>  (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and  <e2> cocaine </e2>  and the oral self-administration of ethanol and nicotine in rats; 
false	Both ibogaine and  <e1> 18-MC </e1>  ameliorate  <e2> opioid </e2>  withdrawal signs. 
false	Both  <e1> 18-MC </e1>  and ibogaine are sequestered in fat and, like  <e2> ibogaine </e2> , 18-MC probably has an active metabolite. 
false	Both ibogaine and  <e1> 18-MC </e1>  decrease extracellular levels of dopamine in the nucleus accumbens, but only  <e2> ibogaine </e2>  increases extracellular levels of serotonin in the nucleus accumbens. 
false	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and  <e1> cocaine </e1>  and the oral self-administration of ethanol and  <e2> nicotine </e2>  in rats; 
false	Both  <e1> ibogaine </e1>  and  <e2> 18-MC </e2>  block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 
effect	Both  <e1> ibogaine </e1>  and 18-MC block  <e2> morphine </e2> -induced and nicotine-induced dopamine release in the nucleus accumbens; 
false	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and  <e1> cocaine </e1>  and the oral self-administration of  <e2> ethanol </e2>  and nicotine in rats; 
false	Both 18-MC and  <e1> ibogaine </e1>  are sequestered in fat and, like  <e2> ibogaine </e2> , 18-MC probably has an active metabolite. 
false	Both  <e1> ibogaine </e1>  and  <e2> 18-MC </e2>  decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital,  <e1> glutethimide </e1> ,  <e2> chloral hydrate </e2>  and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of  <e1> anticoagulant </e1>  interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving  <e2> coumarin </e2>  therapy. 
false	Both 18-MC and ibogaine are sequestered in fat and, like  <e1> ibogaine </e1> ,  <e2> 18-MC </e2>  probably has an active metabolite. 
false	The intensity, uniformity and time course of anticoagulant interference by  <e1> phenobarbital </e1> , secobarbital, glutethimide, chloral hydrate and  <e2> methaqualone </e2>  were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of anticoagulant interference by  <e1> phenobarbital </e1> , secobarbital, glutethimide,  <e2> chloral hydrate </e2>  and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	Anticoagulant inhibition was observed during the administration of phenobarbital,  <e1> secobarbital </e1>  and  <e2> glutethimide </e2> ; 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital,  <e1> secobarbital </e1> ,  <e2> glutethimide </e2> , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
int	Clinical implications of  <e1> warfarin </e1>  interactions with five  <e2> sedatives </e2> .
false	While 18-MC and  <e1> ibogaine </e1>  have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than  <e2> ibogaine </e2>  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 
false	Anticoagulant inhibition was observed during the administration of  <e1> phenobarbital </e1> , secobarbital and  <e2> glutethimide </e2> ; 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital,  <e1> glutethimide </e1> , chloral hydrate and  <e2> methaqualone </e2>  were systematically investigated in 16 patients receiving coumarin therapy. 
false	In the present study, the  <e1> atypical antipsychotic </e1>  clozapine was tested in combination with an active dose of  <e2> PCP </e2>  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 
false	These results suggest that acute dosing with  <e1> clozapine </e1>  would not affect behaviors most closely associated with  <e2> PCP </e2>  intoxication. 
false	 <e1> Resveratrol </e1>  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  <e2> noradrenaline </e2>  (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 
false	Combinations of  <e1> clozapine </e1>  and  <e2> phencyclidine </e2> : effects on drug discrimination and behavioral inhibition in rats.
false	Concurrent administration of  <e1> indinavir </e1>  and didanosine significantly reduces the level of exposure to  <e2> indinavir </e2> , but it is unclear how soon after didanosine administration indinavir may be given safely. 
false	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of  <e1> indinavir </e1>  administered 1 h after  <e2> didanosine </e2>  administration. 
false	In  <e1> noradrenaline </e1> -precontracted arteries from dietary-obese rats, responses to  <e2> resveratrol </e2>  were not attenuated by endothelial denudation, indicating an action independent of the endothelium. 
false	Concurrent administration of indinavir and  <e1> didanosine </e1>  significantly reduces the level of exposure to  <e2> indinavir </e2> , but it is unclear how soon after didanosine administration indinavir may be given safely. 
false	We compared  <e1> indinavir </e1>  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of  <e2> indinavir </e2>  administered 1 h after didanosine administration. 
false	If taken 1 hour before  <e1> indinavir </e1>  (IDV),  <e2> didanosine </e2>  does not affect IDV exposure, despite persistent buffering effects.
false	The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa- <e1> s <e2> elective opioids </e1>  </e2>  was significantly reduced when 1% but not < 
false	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride ( <e1> verapamil </e1> ), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( <e2> AOM </e2> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of  <e1> bombesin </e1>  and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e2> azoxymethane </e2>  (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a  <e1> calcium channel blocker </e1> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( <e2> AOM </e2> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	Although  <e1> verapamil </e1>  administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by  <e2> bombesin </e2>  or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. 
false	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of  <e1> AOM </e1>  (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of  <e2> verapamil </e2>  (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 
false	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of  <e1> bombesin </e1>  (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of  <e2> verapamil </e2>  (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 
effect	There is thus an enhancement effect of  <e1> PGF2alpha </e1>  upon the reaction of placental vessels to  <e2> oxytocin </e2>  in vitro.
false	 <e1> Carbamazepine </e1>  overdose recognized by a  <e2> tricyclic antidepressant </e2>  assay.
false	Cypermethrin-induced oxidative stress in rat brain and liver is prevented by  <e1> vitamin E </e1>  or  <e2> allopurinol </e2> .
effect	Thus, the results suggest that  <e1> cypermethrin </e1>  exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and  <e2> Vitamin E </e2> .
false	In seven experiments reactions to norepinephrine and  <e1> oxytocin </e1>  were  <e2> PGF2alpha </e2> . 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an  <e1> omega-agatoxin IVA </e1> -sensitive (P-type) channel and nimodipine/ <e2> omega-conotoxin GVIA </e2> /omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e1> omega-conotoxin GVIA </e1> -sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/ <e2> omega-agatoxin VIA </e2> -resistant (presumptive Q-type) channel. 
false	In this study we investigated the effect of  <e1> ginsenosides </e1>  on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers  <e2> nimodipine </e2>  (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e1> omega-conotoxin GVIA </e1> -sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/ <e2> omega-conotoxin GVIA </e2> /omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an  <e1> omega-agatoxin IVA </e1> -sensitive (P-type) channel and  <e2> nimodipine </e2> /omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type),  <e1> omega-conotoxin GVIA </e1>  (N-type), or  <e2> omega-agatoxin IVA </e2>  (P-type) in bovine chromaffin cells. 
effect	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or  <e1> rifabutin </e1> ) and  <e2> ofloxacin </e2> . 
false	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e1> selective Ca(2+) channel blockers </e1>  nimodipine (L-type), omega-conotoxin GVIA (N-type), or  <e2> omega-agatoxin IVA </e2>  (P-type) in bovine chromaffin cells. 
false	When combined with  <e1> ofloxacin </e1> , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of  <e2> rifampicin </e2>  (or rifabutin) and ofloxacin. 
false	The effects of  <e1> ruthenium red </e1>  (RR) on inositol 1,4,5-trisphosphate ( <e2> InsP(3) </e2> )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 
false	The effects of ruthenium red (RR) on  <e1> inositol 1,4,5-trisphosphate </e1>  ( <e2> InsP(3) </e2> )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 
false	Effect of  <e1> rofecoxib </e1>  on the pharmacokinetics of  <e2> digoxin </e2>  in healthy volunteers.
false	In contrast, in isolated single pancreatic acinar cells,  <e1> RR </e1>  had no effect on  <e2> InsP(3) </e2> -induced responses. 
false	For  <e1> digoxin </e1>  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo +  <e2> digoxin </e2> ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e1> prednisone </e1>  with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	 <e1> Antiretroviral </e1>  regimens consisted of two  <e2> reverse transcriptase inhibitors </e2>  and one protease inhibitor. 
false	Concomitant cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and  <e2> prednisone </e2>  chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and  <e2> prednisone </e2>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e2> doxorubicin </e2> , teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> ,  <e2> doxorubicin </e2> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e1> teniposide </e1> , and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e2> cyclophosphamide </e2> , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin,  <e2> vincristine </e2> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e2> cyclophosphamide </e2> , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1> cyclophosphamide </e1> , doxorubicin, teniposide, and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e2> cyclophosphamide </e2> , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	 <e1> Sertraline </e1>  neutralized the increase of glycemia induced by oral  <e2> glucose </e2>  overload. 
false	Concomitant  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and  <e2> prednisone </e2>  chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e1> prednisone </e1>  with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	Imipramine (5 mg/kg), moclobemide (30 mg/kg),  <e1> clonazepam </e1>  (0.25 mg/kg), fluoxetine (20 mg/kg)  <e2> sertraline </e2>  (30 mg/kg) or vehicle was administered. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	The effects of ruthenium red ( <e1> RR </e1> ) on  <e2> inositol 1,4,5-trisphosphate </e2>  (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 
false	Imipramine (5 mg/kg),  <e1> moclobemide </e1>  (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg)  <e2> sertraline </e2>  (30 mg/kg) or vehicle was administered. 
false	Fluoxetine and  <e1> moclobemide </e1>  increased blood  <e2> glucose </e2>  at different times after the glucose overload. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e2> doxorubicin </e2> , teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	 <e1> Imipramine </e1>  (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg)  <e2> sertraline </e2>  (30 mg/kg) or vehicle was administered. 
false	Effect of  <e1> dofetillide </e1>  on the pharmacokinetics of  <e2> digoxin </e2> .
false	Five days of  <e1> dofetilide </e1>  treatment did not significantly affect steady-state pharmacokinetic variables of  <e2> digoxin </e2>  compared with placebo; 
false	The half-life of ketamine in plasma and brain was longer in the presence of  <e1> halothane </e1>  than when  <e2> ketamine </e2>  was given alone. 
false	The half-life of  <e1> ketamine </e1>  in plasma and brain was longer in the presence of halothane than when  <e2> ketamine </e2>  was given alone. 
mechanism	The half-life of  <e1> ketamine </e1>  in plasma and brain was longer in the presence of  <e2> halothane </e2>  than when ketamine was given alone. 
false	The effect of  <e1> rifampin </e1>  on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after  <e2> rifampin </e2>  withdrawal. 
false	Formulation of fluorescence labelled bacitracin and insulin in unconjugated  <e1> NaCMC </e1>  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  <e2> CMC-Cys </e2> 7.3 a significantly improved permeation was observed (R= 1.3). 
false	Conjugation at  <e1> NaCMC </e1>  with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e2> NaFlu </e2>  and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	The effect of  <e1> rifampin </e1>  on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  <e2> rifampin </e2>  and extended a similar length of time after rifampin withdrawal. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose ( <e1> NaCMC </e1> ) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of  <e2> sodium fluorescein </e2>  (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	Conjugation at  <e1> NaCMC </e1>  with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and  <e2> insulin </e2>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	Conjugation at NaCMC with  <e1> cysteine </e1>  moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and  <e2> insulin </e2>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of  <e1> NaFlu </e1>  compared to  <e2> NaCMC </e2>  alone. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose ( <e1> NaCMC </e1> ) and  <e2> carboxymethylcellulose-cysteine </e2>  (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	Decreasing the concentration of  <e1> CMC-Cys </e1> , exhibiting 7.3% (m/m) of immobilised  <e2> cysteine </e2>  (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 
false	Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  <e1> NaFlu </e1>  to 1.3 and 1% (m/v)  <e2> NaCMC </e2>  conjugated with cysteine further enhanced the permeation. 
false	NaCMC at 1% (m/v) in the presence of free  <e1> cysteine </e1>  had no significant effect on the R-value of NaFlu compared to  <e2> NaCMC </e2>  alone. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and  <e1> carboxymethylcellulose-cysteine </e1>  ( <e2> CMC-Cys </e2> ) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine ( <e1> CMC-Cys </e1> ) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs,  <e2> bacitracin </e2>  and insulin. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of  <e1> sodium fluorescein </e1>  ( <e2> NaFlu </e2> ) and model peptide drugs, bacitracin and insulin. 
false	 <e1> NaCMC </e1>  at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to  <e2> NaCMC </e2>  alone. 
false	Serial plasma and urine samples for measurement of amprenavir,  <e1> rifabutin </e1> , and rifampin and their  <e2> 25-O-desacetyl metabolites </e2> , were measured by high-performance liquid chromatography. 
false	Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received  <e1> amprenavir </e1>  plus  <e2> rifampin </e2>  for 4 days. 
false	Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of  <e1> rifabutin </e1>  by 2.93-fold and the AUC(ss) of  <e2> 25-O-desacetylrifabutin </e2>  by 13.3-fold. 
false	Pharmacokinetic Interaction between  <e1> amprenavir </e1>  and  <e2> rifabutin </e2>  or rifampin in healthy males.
false	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with  <e1> rifabutin </e1>  or  <e2> rifampin </e2>  and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 
false	Serial plasma and urine samples for measurement of  <e1> amprenavir </e1> , rifabutin, and rifampin and their  <e2> 25-O-desacetyl metabolites </e2> , were measured by high-performance liquid chromatography. 
mechanism	 <e1> Amprenavir </e1>  significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of  <e2> 25-O-desacetylrifabutin </e2>  by 13.3-fold. 
false	Cohort 1 then received amprenavir plus  <e1> rifabutin </e1>  for 10 days, and cohort 2 received  <e2> amprenavir </e2>  plus rifampin for 4 days. 
false	The thiazolidinediones ( <e1> rosiglitazone </e1>  and pioglitazone), a new class of oral  <e2> antidiabetic agents </e2> , are "insulin sensitizers" 
false	 <e1> Amprenavir </e1>  inhibits the ERMBT, and  <e2> rifampin </e2>  and rifabutin are equipotent inducers of the ERMBT.
false	Amprenavir inhibits the ERMBT, and  <e1> rifampin </e1>  and  <e2> rifabutin </e2>  are equipotent inducers of the ERMBT.
false	 <e1> Arginine </e1> , in the absence of  <e2> glucose </e2>  or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 
false	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM),  <e1> glucose </e1>  (100 or 150 mg. per 100 ml.), and  <e2> theophylline </e2>  (10 mM). 
false	Arginine, in the absence of  <e1> glucose </e1>  or  <e2> theophylline </e2> , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 
false	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of  <e1> arginine </e1>  (20mM), glucose (100 or 150 mg. per 100 ml.), and  <e2> theophylline </e2>  (10 mM). 
false	Animals dosed with  <e1> 1,3-difluoroacetone </e1>  did not display the 2-3 hour lag phase in either  <e2> (-)-erythro-fluorocitrate </e2>  synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 
false	We conclude that the prophylactic and antidotal properties of  <e1> 4-methylpyrazole </e1>  seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to  <e2> 1,3-difluoroacetone </e2>  in the committed step of the toxic pathway.
false	However, administration of  <e1> 4-methylpyrazole </e1>  (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing  <e2> (-)-erythro-fluorocitrate </e2>  synthesis and did not diminish fluoride or citrate accumulation in vivo. 
false	We demonstrate that the conversion of  <e1> 1,3-difluoro-2-propanol </e1>  to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from  <e2> 1,3-difluoro-2-propanol </e2> . 
false	We demonstrate that the conversion of 1,3-difluoro-2-propanol to  <e1> 1,3-difluoroacetone </e1>  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from  <e2> 1,3-difluoro-2-propanol </e2> . 
false	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of  <e1> 1,3-difluoro-2-propanol </e1>  (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in  <e2> 1,3-difluoro-2-propanol </e2> -intoxicated animals. 
false	We demonstrate that the conversion of  <e1> 1,3-difluoro-2-propanol </e1>  to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  <e2> (-)-erythro-fluorocitrate </e2>  from 1,3-difluoro-2-propanol. 
false	 <e1> n-dodecyl gallate </e1>  showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude  <e2> tannic acid </e2> . 
false	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and  <e1> desmethyldiltiazem </e1>  were unchanged after coadministration of sirolimus, and no potentiation of the effects of  <e2> diltiazem </e2>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of  <e1> diltiazem </e1> , desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of  <e2> diltiazem </e2>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem,  <e1> desacetyldiltiazem </e1> , and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of  <e2> diltiazem </e2>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of  <e1> sirolimus </e1> , a single oral 120-mg dose of  <e2> diltiazem </e2> , and the two drugs given together. 
mechanism	Pharmacokinetic interaction between single oral doses of  <e1> diltiazem </e1>  and  <e2> sirolimus </e2>  in healthy volunteers.
false	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a  <e1> macrolide immunosuppressant </e1>  metabolized by CYP3A4, and the  <e2> calcium channel blocker </e2>  diltiazem was studied in 18 healthy subjects. 
false	OBJECTIVE: Our objective was to examine the interaction between  <e1> fluvoxamine </e1>  and  <e2> tolbutamide </e2>  to confirm that fluvoxamine inhibits CYP2C9. 
mechanism	Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when  <e1> sirolimus </e1>  was given with  <e2> diltiazem </e2> . 
false	The clearance by means of  <e1> 4-hydroxytolbutamide </e1>  and  <e2> carboxytolbutamide </e2>  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 
false	Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites,  <e1> 4-hydroxytolbutamide </e1>  and  <e2> carboxytolbutamide </e2>  by means of HPLC. 
false	Apparent oral clearance and volume of distribution of  <e1> sirolimus </e1>  decreased with 38% and 45%, respectively, when sirolimus was given with  <e2> diltiazem </e2> . 
false	 <e1> Cyclosporine </e1>  doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered  <e2> everolimus </e2>  dose level (P = .13, .82, and .76, respectively). 
false	Potential differences in  <e1> cyclosporine </e1>  dosing and pharmacokinetics at different levels of  <e2> everolimus </e2>  exposure were assessed in the context of ANOVA. 
false	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of  <e1> everolimus </e1>  and cyclosporine (INN,  <e2> ciclosporin </e2> ) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 
false	Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive  <e1> ADL 8-2698 </e1>  (4 mg) or placebo and intravenous  <e2> morphine </e2>  (0.15 mg/kg) or to receive oral and intravenous placebo. 
false	ADL-8-2698 is a novel  <e1> peripherally restricted opioid antagonist </e1>  that may selectively prevent  <e2> opioid </e2> -induced gastrointestinal effects without reversing analgesia. 
effect	 <e1> ADL-8-2698 </e1>  is a novel peripherally restricted opioid antagonist that may selectively prevent  <e2> opioid </e2> -induced gastrointestinal effects without reversing analgesia. 
false	OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of  <e1> clarithromycin </e1>  and  <e2> simvastatin </e2> . 
mechanism	CONCLUSIONS:  <e1> Macrolide antibiotics </e1>  inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin,  <e2> cerivastatin </e2> , lovastatin, simvastatin). 
false	OBJECTIVE: Our objective was to examine the interaction between  <e1> fluvoxamine </e1>  and tolbutamide to confirm that  <e2> fluvoxamine </e2>  inhibits CYP2C9. 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin,  <e1> lovastatin </e1> ,  <e2> simvastatin </e2> ). 
false	 <e1> Quetiapine fumarate </e1>  ('Seroquel') is a newly introduced  <e2> atypical antipsychotic </e2>  with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of  <e1> acetaminophen </e1>  with theophylline, phenobarbital with acetaminophen, and  <e2> valproic acid </e2>  with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> /valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	Acetaminophen, lidocaine, phenobarbital,  <e1> quinidine </e1> ,  <e2> theophylline </e2> , and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> ,  <e2> phenobarbital </e2> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of  <e1> acetaminophen </e1>  with theophylline, phenobarbital with  <e2> acetaminophen </e2> , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e1> valproic acid </e1> , quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
mechanism	 <e1> Acetaminophen </e1>  diminished the binding of  <e2> theophylline </e2>  to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e1> quinidine </e1> /lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e1> valproic acid </e1> / <e2> phenobarbital </e2> . 
effect	Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and  <e1> valproic acid </e1>  with  <e2> phenobarbital </e2>  at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/ <e1> theophylline </e1> ,  <e2> lidocaine </e2> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Acetaminophen, lidocaine,  <e1> phenobarbital </e1> , quinidine, theophylline, and  <e2> valproic acid </e2>  were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/ <e2> quinidine </e2> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen,  <e2> phenobarbital </e2> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of acetaminophen with  <e1> theophylline </e1> ,  <e2> phenobarbital </e2>  with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> / <e2> acetaminophen </e2> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Acetaminophen, lidocaine, phenobarbital, quinidine,  <e1> theophylline </e1> , and  <e2> valproic acid </e2>  were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e1> theophylline </e1> / <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> ,  <e2> phenobarbital </e2> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	Similarly dialyzed were phenobarbital,  <e1> quinidine </e1> , and  <e2> theophylline </e2> , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 
false	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of  <e1> phenytoin </e1>  and other  <e2> drugs </e2>  had not changed. 
false	The interaction may be a result of inhibition of both  <e1> CYP2C9 </e1>  and 2C19 by  <e2> fluvoxamine </e2> .
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Acetaminophen, lidocaine,  <e1> phenobarbital </e1> ,  <e2> quinidine </e2> , theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	The serum concentration of  <e1> phenytoin </e1>  increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other  <e2> drugs </e2>  had not changed. 
false	CONCLUSIONS/INTERPRETATION:  <e1> Glucose </e1>  and  <e2> insulin </e2>  can exert additive vasodilator properties on renal and ocular circulation. 
mechanism	Previous studies have demonstrated a significant reduction in the oral bioavailability of  <e1> trovafloxacin </e1>  and ciprofloxacin when administered concomitantly with an intravenous  <e2> opiate </e2>  such as morphine. 
false	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous  <e1> opiate </e1>  such as  <e2> morphine </e2> . 
false	Lack of interaction between  <e1> levofloxacin </e1>  and  <e2> oxycodone </e2> : pharmacokinetics and drug disposition.
false	Two studies were conducted in HIV-infected subjects to assess the potential for  <e1> azithromycin </e1>  to interact with  <e2> zidovudine </e2>  and dideoxyinosine. 
false	It was concluded that oral  <e1> oxycodone </e1>  and  <e2> levofloxacin </e2>  can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.
false	 <e1> Antiretroviral </e1>  plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for  <e2> dideoxyinosine </e2> . 
mechanism	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and  <e1> ciprofloxacin </e1>  when administered concomitantly with an intravenous opiate such as  <e2> morphine </e2> . 
false	There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for  <e1> levofloxacin </e1>  versus  <e2> levofloxacin </e2> /oxycodone regimens. 
false	Lack of an effect of azithromycin on the disposition of  <e1> zidovudine </e1>  and  <e2> dideoxyinosine </e2>  in HIV-infected patients.
false	The influence of  <e1> midazolam </e1>  and diazepam on antinociceptive effect of  <e2> morphine </e2>  (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
effect	 <e1> Midazolam </e1>  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  <e2> morphine </e2> , metamizol (only in the tail-flick test) and indomethacin.
false	Effect of  <e1> diazepam </e1>  and midazolam on the antinociceptive effect of  <e2> morphine </e2> , metamizol and indomethacin in mice.
false	Effect of diazepam and midazolam on the antinociceptive effect of morphine,  <e1> metamizol </e1>  and  <e2> indomethacin </e2>  in mice.
false	Effect of  <e1> diazepam </e1>  and midazolam on the antinociceptive effect of morphine,  <e2> metamizol </e2>  and indomethacin in mice.
false	The influence of midazolam and  <e1> diazepam </e1>  on antinociceptive effect of morphine (10 mg/kg),  <e2> metamizol </e2>  (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	The influence of  <e1> midazolam </e1>  and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and  <e2> indomethacin </e2>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	The influence of  <e1> midazolam </e1>  and diazepam on antinociceptive effect of morphine (10 mg/kg),  <e2> metamizol </e2>  (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	Endothelium-intact aortic rings from high- <e1> estradiol </e1>  rats were supersensitive to noradrenaline when compared to vehicle-,  <e2> progesterone </e2> - and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to  <e1> noradrenaline </e1>  when compared to vehicle-,  <e2> progesterone </e2> - and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	Influence of estradiol and  <e1> progesterone </e1>  on the sensitivity of rat thoracic aorta to  <e2> noradrenaline </e2> .
false	The aim of this study was to investigate the effects of low and high doses of  <e1> estradiol </e1> , and of  <e2> progesterone </e2>  on the response to noradrenaline in rat thoracic aorta. 
false	No interactions have been observed with beta-receptor blockers,  <e1> calcium antagonists </e1> , thiazide and  <e2> loop diuretics </e2>  and ACE inhibitors. 
false	Since the arrival of oral  <e1> erection-supporting medication </e1> , patients want to know how safe sexual activity is in cardiovascular disease in general and during use of  <e2> erection-supporting medication </e2>  in particular. 
false	No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and  <e1> loop d <e2> iuretics </e1>  </e2>  and ACE inhibitors. 
false	and phase 3 (days 45-52):  <e1> cisapride </e1>  10 mg 4 times/day (days 45-51) plus  <e2> fluoxetine </e2>  20 mg/day (days 45-52). 
false	There were no clinically significant changes in corrected QT intervals during administration of  <e1> cisapride </e1>  alone or with  <e2> fluoxetine </e2> . 
false	Improvements in general cognitive function seen with  <e1> olanzapine </e1>  treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or  <e2> haloperidol </e2> . 
false	In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  <e1> risperidone </e1> , only bodyweight gain occurred significantly more frequently with  <e2> olanzapine </e2> . 
false	In the first double-blind comparative study (28-week) of  <e1> olanzapine </e1>  and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than  <e2> risperidone </e2>  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 
false	Olanzapine, a  <e1> thienobenzodiazepine derivative </e1> , is a  <e2> second generation (atypical) antipsychotic agent </e2>  which has proven efficacy against the positive and negative symptoms of schizophrenia. 
false	Several studies indicate that  <e1> olanzapine </e1>  has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of  <e2> olanzapine </e2>  in the treatment of depressive symptomatology. 
false	Compared with  <e1> risperidone </e1> ,  <e2> olanzapine </e2>  has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. 
false	In addition,  <e1> olanzapine </e1>  is not associated with a risk of agranulocytosis as seen with  <e2> clozapine </e2>  or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 
false	Improvements in general cognitive function seen with  <e1> olanzapine </e1>  treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either  <e2> risperidone </e2>  or haloperidol. 
false	The availability of potent  <e1> non-nucleoside reverse transcriptase inhibitor </e1>  (NNRTI)-based regimens for  <e2> antiretroviral </e2>  therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	The availability of potent  <e1> non-nucleoside reverse transcriptase inhibitor </e1>  (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor ( <e2> PI </e2> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	The 1-year risk of relapse (rehospitalisation) was significantly lower with  <e1> olanzapine </e1>  than with  <e2> haloperidol </e2>  treatment. 
false	Both efavirenz and  <e1> nevirapine </e1>  have been compared to triple therapy with the  <e2> PI </e2>  indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 
false	Both efavirenz and nevirapine have been compared to triple therapy with the  <e1> PI </e1>  indinavir over 48 weeks as initial therapy, with similar responses being observed with  <e2> nevirapine </e2>  regimens and superiority observed with efavirenz. 
false	The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding  <e1> protease inhibitor </e1>  ( <e2> PI </e2> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	The emerging roles of  <e1> non-nucleoside reverse transcriptase inhibitors </e1>  in  <e2> antiretroviral </e2>  therapy.
false	Olanzapine is associated with significantly fewer extrapyramidal symptoms than  <e1> haloperidol </e1>  and  <e2> risperidone </e2> . 
false	No data from prospective clinical trials currently exist comparing the 3 approved agents ( <e1> efavirenz </e1> ,  <e2> nevirapine </e2>  or delavirdine). 
false	In comparison with  <e1> haloperidol </e1> , the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  <e2> risperidone </e2> , only bodyweight gain occurred significantly more frequently with olanzapine. 
false	No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz,  <e1> nevirapine </e1>  or  <e2> delavirdine </e2> ). 
false	METHODS: Clinical studies, case reports, and commentaries and editorials concerning  <e1> sildenafil </e1>  published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil,  <e2> Viagra </e2> , and erectile dysfunction. 
false	RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg,  <e1> selective serotonin reuptake inhibitors </e1>  [ <e2> SSRIs </e2> ]). 
false	METHODS:  <e1> Hydrocortisone </e1>  (100 mg) and  <e2> d-amphetamine </e2>  (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. 
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e2> ketamine </e2>  or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1> ouabain </e1> , with ketamine or  <e2> Innovar </e2>  than with pentobarbital. 
effect	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> , Innovar Vet, or pentobarbital, the dosage of  <e2> ouabain </e2>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine,  <e2> Innovar Vet </e2> , or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> , Innovar Vet, or  <e2> pentobarbital </e2> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine,  <e1> Innovar Vet </e1> , or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e2> ouabain </e2> , with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> , Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with  <e2> pentobarbital </e2> . 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1> ouabain </e1> , with ketamine or Innovar than with  <e2> pentobarbital </e2> . 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of  <e1> Innovar </e1> , ketamine, or droperidol but not after administration of  <e2> fentayl </e2>  alone or after pentobarbital.
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine,  <e1> Innovar Vet </e1> , or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or  <e2> Innovar </e2>  than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or  <e1> pentobarbital </e1> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with  <e2> pentobarbital </e2> . 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of  <e1> ouabain </e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or  <e2> Innovar </e2>  than with pentobarbital. 
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or  <e2> Innovar </e2>  than with pentobarbital. 
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine, Innovar Vet, or  <e2> pentobarbital </e2> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	Among the  <e1> polyene antibiotics </e1> , many, like  <e2> filipin </e2> , cannot be used clinically because they are toxic; 
false	 <e1> Gentamicin </e1>  did not interfere with the activity of  <e2> clindamycin </e2>  within the range of concentrations tested (0.1 to 100 mug/ml); 
false	The  <e1> antifungal drug </e1> ,  <e2> miconazole nitrate </e2> , inhibits the growth of several species of Candida. 
mechanism	(1968, 1970), the higher serum concentrations of  <e1> penicillins </e1>  and cephaloridine reached after administration of  <e2> probenecid </e2>  are due not only to slower renal elimination but also to an altered distribution in the body. 
false	No significant difference was found between the mean values of the volume of distribution of  <e1> cloxacillin </e1>  with and without  <e2> probenecid </e2>  (13.0 and 12.6 liters, respectively). 
false	To determine whether probenecid has a direct effect on the distribution of  <e1> cloxacillin </e1> , the elimination and distribution of  <e2> cloxacillin </e2>  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 
false	The initiation of  <e1> alcohol </e1>  or  <e2> nicotine </e2>  use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. 
false	[Dose-time effects of competitive displacement of radiopertechnetate by  <e1> sodium perchlorate </e1>  following oral and intravenous administration];The effect of various doses of s <e2> odium perchlorate  </e2> in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 
false	[Dose-time effects of competitive displacement of  <e1> radiopertechnetate </e1>  by  <e2> sodium perchlorate </e2>  following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 
false	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e1> sirolimus </e1> , in combination with cyclosporine or  <e2> tacrolimus </e2> , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
false	Sirolimus works differently from the  <e1> immunosuppressants </e1>  currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with  <e2> cyclosporine </e2>  or tacrolimus. 
false	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or  <e1> tacrolimus </e1> , might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e2> cyclosporine </e2>  or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
false	 <e1> Sirolimus </e1> : mammalian target of  <e2> rapamycin </e2>  inhibitor to prevent kidney rejection.
false	The effects of  <e1> chlordiazepoxide </e1> , amphetamine and  <e2> cocaine </e2>  on bar-press behavior in normal and genetically nervous dogs.
false	The effects of  <e1> chlordiazepoxide </e1> ,  <e2> amphetamine </e2>  and cocaine on bar-press behavior in normal and genetically nervous dogs.
false	Moreover, additional interaction studies with  <e1> niacin </e1>  and  <e2> propranolol </e2>  have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 
false	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on  <e1> fluvastatin </e1>  plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of  <e2> digoxin </e2>  relative to control data. 
false	It is structurally distinct from the other currently available  <e1> HMGCoA reductase inhibitors </e1>  (lovastatin,  <e2> simvastatin </e2> , and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 
false	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving  <e1> digoxin </e1>  resulted in no difference in the extent of bioavailability of  <e2> digoxin </e2>  relative to control data. 
false	Moreover, additional interaction studies with  <e1> niacin </e1>  and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of  <e2> digoxin </e2>  relative to control data. 
false	Those for which effectiveness is reported includes diphenhydramine,  <e1> hydroxyzine </e1> , orphenadrine, pyrilamine, phenyltoloxamine,  <e2> promethazine </e2> , methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine,  <e1> pyrilamine </e1> , phenyltoloxamine,  <e2> promethazine </e2> , methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine,  <e1> hydroxyzine </e1> , orphenadrine,  <e2> pyrilamine </e2> , phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine,  <e1> pyrilamine </e1> , phenyltoloxamine, promethazine, methdilazine, and  <e2> tripelennamine </e2> . 
false	Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of  <e1> warfarin </e1>  and  <e2> fluvastatin </e2> . 
false	Those for which effectiveness is reported includes diphenhydramine,  <e1> hydroxyzine </e1> , orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and  <e2> tripelennamine </e2> . 
effect	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that p <e1> icrotoxin  </e1> (1 mg/kg) removes the antiedematous action of diazepam, p <e2> henazepam, </e2>  phenibut and amizyl and reduces the action of phentolamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine,  <e1> phenyltoloxamine </e1> , promethazine, methdilazine, and  <e2> tripelennamine </e2> . 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, p <e1> henazepam, </e1>  phenibut and amizyl and reduces the action of p <e2> hentolamine. </e2>  
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, p <e1> henazepam, </e1>  phenibut and a <e2> mizyl  </e2> and reduces the action of phentolamine. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e1> H-spiroperidol  </e1> and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e1> H-spiroperidol  </e1> binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e1> aloperidol  </e1> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e2> pomorphine  </e2> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of d <e1> iazepam, </e1>  phenazepam, phenibut and amizyl and reduces the action of p <e2> hentolamine. </e2>  
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e1> pomorphine  </e1> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e2> neuroleptics </e2> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e1> yreneperone  </e1> (0.25 mg/kg) resulted in the reduced interaction between 3 <e2> H-spiroperidol  </e2> and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e1> aloperidol  </e1> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e2> H-spiroperidol  </e2> and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	The second response is due to a release of norepinephrine from nerves and was potentiated by  <e1> ouabain </e1>  through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by  <e2> ouabain </e2> . 
false	 <e1> Palytoxin </e1>  ( <e2> PTX </e2> ), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. 
effect	Exposure of the muscle to  <e1> ouabain </e1>  (10(-5) M) markedly increased the  <e2> PTX </e2> -induced release. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e1> neuroleptics </e1> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e2> pomorphine  </e2> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	Dual effect of  <e1> ouabain </e1>  on the  <e2> palytoxin </e2> -induced contraction and norepinephrine release in the guinea-pig vas deferens.
false	The intestinal absorption of  <e1> arsenate </e1> ( <e2> As(V) </e2> ) has been investigated in the chick by means of the in situ ligated duodenal loop technique. 
false	 <e1> Spermine </e1> , and to a lesser extent,  <e2> spermidine </e2> , enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction. 
false	Slow-channel calcium blockers, such as  <e1> verapamil </e1> , diltiazem and  <e2> nifedipine </e2> , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 
false	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular  <e1> beta-endorphin </e1>  and  <e2> morphine </e2>  was then studied. 
effect	Intraventricular injection of  <e1> naloxone </e1>  at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and  <e2> morphine </e2> . 
false	The blockade of the spinal endorphinergic system by intrathecal  <e1> naloxone </e1>  on the production of tail-flick inhibition induced by intraventricular  <e2> beta-endorphin </e2>  and morphine was then studied. 
false	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  <e1> beta-endorphin </e1> , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  <e2> beta-endorphin </e2>  (16 micrograms). 
false	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of  <e1> beta-endorphin </e1>  but not morphine-induced tail-flick inhibition, and suggest that intraventricular  <e2> beta-endorphin </e2>  and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	The results indicate that a spinal  <e1> naloxone </e1> -sensitive endorphinergic system is involved in the production of beta-endorphin but not  <e2> morphine </e2> -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	The blockade of the spinal endorphinergic system by intrathecal  <e1> naloxone </e1>  on the production of tail-flick inhibition induced by intraventricular beta-endorphin and  <e2> morphine </e2>  was then studied. 
false	The neurochemical and functional consequences following  <e1> MPTP </e1>  administration to the rat were evaluated and compared to similar effects following  <e2> methamphetamine </e2>  administration. 
effect	The  <e1> MPTP </e1> -induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of  <e2> apomorphine </e2>  in rats responding in a schedule controlled paradigm. 
false	The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of  <e1> amphetamine </e1>  and a supersensitivity to the disruptive effects of  <e2> apomorphine </e2>  in rats responding in a schedule controlled paradigm. 
false	Higher concentrations of  <e1> dexamethasone </e1>  (10(-8) - 10(-6) M) or  <e2> retinyl acetate </e2>  (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 
false	 <e1> Dexamethasone </e1>  at 10(-10) M or  <e2> retinyl acetate </e2>  at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 
false	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing  <e1> transferrin </e1>  alone, they modify the mitogenic effect of  <e2> EGF </e2>  and insulin. 
effect	These results suggest that both  <e1> dexamethasone </e1>  and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e2> insulin </e2>  and EGF.
false	Although neither dexamethasone nor  <e1> retinyl acetate </e1>  affected the proliferation of prostatic epithelium in RPMI1640 containing  <e2> transferrin </e2>  alone, they modify the mitogenic effect of EGF and insulin. 
effect	Higher concentrations of  <e1> dexamethasone </e1>  (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of  <e2> EGF </e2> . 
effect	However,  <e1> retinyl acetate </e1>  stimulated, but did not significantly inhibit, proliferation in the presence of  <e2> insulin </e2> . 
effect	Although neither dexamethasone nor  <e1> retinyl acetate </e1>  affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and  <e2> insulin </e2> . 
false	For the  <e1> calcium-entry blocking agents </e1>  now available in the United States ( <e2> verapamil </e2> , nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 
effect	Although neither dexamethasone nor  <e1> retinyl acetate </e1>  affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of  <e2> EGF </e2>  and insulin. 
false	For the calcium-entry blocking agents now available in the United States (verapamil,  <e1> nifedipine </e1>  and  <e2> diltiazem </e2> ), these data appeared well after clinical patterns of use evolved. 
false	These results suggest that both  <e1> dexamethasone </e1>  and retinyl acetate, and possibly other  <e2> glucocorticoids </e2>  and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
false	For the  <e1> calcium-entry blocking agents </e1>  now available in the United States (verapamil, nifedipine and  <e2> diltiazem </e2> ), these data appeared well after clinical patterns of use evolved. 
effect	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or  <e1> retinyl acetate </e1>  (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of  <e2> EGF </e2> . 
false	The pharmacokinetic variables for  <e1> digoxin </e1>  were determined after a 1.0 mg intravenous dose of  <e2> digoxin </e2>  in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 
mechanism	 <e1> Amiodarone </e1>  is known to raise serum  <e2> digoxin </e2>  levels. 
false	These alterations in digoxin pharmacokinetics produced by  <e1> amiodarone </e1>  explain the increase in serum  <e2> digoxin </e2>  level that has been observed when this drug combination has been used clinically.
false	Because the nitrosourea  <e1> CCNU </e1>  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer  <e2> misonidazole </e2> . 
false	The pharmacokinetic variables for  <e1> digoxin </e1>  were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral  <e2> amiodarone </e2> , 400 mg daily for 3 weeks. 
mechanism	This report describes two cases in which  <e1> theophylline </e1>  clearance accelerated markedly with concomitant  <e2> phenytoin </e2>  administration. 
false	The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of  <e1> phencyclidine </e1>  ( <e2> PCP </e2> ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 
false	In monkeys, the effects of  <e1> (-)-NANM </e1> , but not  <e2> (+)-NANM </e2>  or PCP, were antagonized by naloxone; 
false	the doses of naloxone required to antagonize the effects of  <e1> (-)-NANM </e1>  were more than 100 times higher than those required to antagonize the effects of  <e2> morphine </e2> . 
effect	In monkeys, the effects of  <e1> (-)-NANM </e1> , but not (+)-NANM or PCP, were antagonized by  <e2> naloxone </e2> ; 
false	In monkeys, the effects of (-)-NANM, but not  <e1> (+)-NANM </e1>  or PCP, were antagonized by  <e2> naloxone </e2> ; 
false	In pigeons, naloxone did not systematically alter the effects of (-)-NANM,  <e1> (+)-NANM </e1>  or  <e2> PCP </e2> . 
false	In monkeys, (-)-NANM was about 10 times more potent than  <e1> (+)-NANM </e1>  in decreasing responding, whereas in pigeons  <e2> (-)-NANM </e2>  was about equipotent with (+)-NANM. 
effect	With combined use, clinicians should be aware, when  <e1> phenytoin </e1>  is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum  <e2> theophylline </e2>  concentrations.
false	In monkeys,  <e1> (-)-NANM </e1>  was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons  <e2> (-)-NANM </e2>  was about equipotent with (+)-NANM. 
false	The behavioral effects of the stereoisomers of N-allylnormetazocine ( <e1> NANM </e1> ) were compared with those of phencyclidine ( <e2> PCP </e2> ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 
false	To determine whether injection of  <e1> thiosulfate </e1>  would permit larger doses of  <e2> cisplatin </e2>  to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 
false	Comparison of  <e1> cisplatin </e1>  pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  <e2> cisplatin </e2> . 
false	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus  <e1> thiosulfate </e1>  to those in patients treated with 100 mg/m2 without  <e2> thiosulfate </e2>  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 
effect	High-dose  <e1> cisplatin </e1>  with  <e2> sodium thiosulfate </e2>  protection.
false	The behavioral effects of the stereoisomers of N-allylnormetazocine ( <e1> NANM </e1> ) were compared with those of  <e2> phencyclidine </e2>  (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 
false	Interactions between treatments with coumaphos, bishydroxycoumarin (an  <e1> anticoagulant </e1> ), trichlorfon (an organophosphorous compound), and  <e2> phenobarbital sodium </e2>  (an inducer of microsomal enzymes) were investigated in sheep. 
false	Interactions between treatments with coumaphos, bishydroxycoumarin (an  <e1> anticoagulant </e1> ),  <e2> trichlorfon </e2>  (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Repeated oral administration of coumaphos in sheep: interactions of  <e1> coumaphos </e1>  with bishydroxycoumarin,  <e2> trichlorfon </e2> , and phenobarbital sodium.
false	Interactions between treatments with coumaphos, bishydroxycoumarin (an  <e1> anticoagulant </e1> ), trichlorfon (an  <e2> organophosphorous compound </e2> ), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin,  <e1> trichlorfon </e1> , and  <e2> phenobarbital sodium </e2> .
false	Repeated oral administration of  <e1> coumaphos </e1>  in sheep: interactions of  <e2> coumaphos </e2>  with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
false	The effects of oral  <e1> neomycin </e1>  on  <e2> ACTH </e2>  induced hypertension were examined in conscious sheep. 
false	The present work involved the administration of both  <e1> ethynyl estradiol </e1>  and  <e2> levonorgestrel </e2>  to groups of rats, followed by determination of the homocysteine excretion rate in urine. 
false	Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of  <e1> trimethyl lead </e1>  ( <e2> TML </e2> ) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle. 
false	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline,  <e1> ethanol </e1>  (2.0 g/kg), physostigmine (0.6 mg/kg) or  <e2> atropine </e2>  (15.0 mg/kg) on separate days. 
false	Hypothermia as an index of the  <e1> disulfiram </e1> - <e2> ethanol </e2>  reaction in the rat.
effect	On the contrary,  <e1> neurotensin </e1>  and  <e2> tuftsin </e2>  were agonists in induction of analgesia. 
false	The aim of this paper was to study the interaction between neurotensin and both  <e1> enkephalins </e1>  or its synthetic analogue D-Ala2-metenkephalinamide, or  <e2> tuftsin </e2> , on the antinonciceptive effect of these peptides in mice after intracisternal injection. 
false	Core temperature was decreased in rats in a dose-dependent manner when  <e1> ethanol </e1>  was administered to rats treated with disulfiram 8 hours before the  <e2> ethanol </e2>  challenge. 
false	The lower rate of absorption in the groups receiving 446 mg  <e1> Fe </e1>  instead of 48 mg of  <e2> Fe </e2>  per kg diet resulted in a decreased renal excretion of cobalt. 
false	Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of  <e1> cobalt </e1>  on  <e2> iron </e2>  absorption and excretion occurred. 
false	 <e1> Cobalt </e1>  excretion was enhanced by supplementary  <e2> cobalt </e2> ; 
mechanism	The lower rate of absorption in the groups receiving 446 mg  <e1> Fe </e1>  instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of  <e2> cobalt </e2> . 
false	The serum estrogen concentrations of estradiol +  <e1> endotoxin </e1> -treated rats decreased by 50%, while those of the  <e2> endotoxin </e2> -treated rats increased (2- to 5-fold). 
false	These results, together with the known relationships between  <e1> estrogen </e1>  and the immune response, suggest that  <e2> estrogens </e2>  affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
false	Effect of  <e1> estradiol </e1>  on  <e2> endotoxin </e2> -induced changes in steroid hormone levels and lethality in male rats.
false	The serum androgen concentrations of estradiol +  <e1> endotoxin </e1> -treated rats did not change significantly, while those of  <e2> endotoxin </e2> -treated rats dropped to 30-40%
effect	Loperamide and  <e1> morphine </e1>  (0.1 and 1.0 mg/kg, s.c.) inhibited the  <e2> dmPGE2 </e2>  (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 
false	The  <e1> 16,16-dimethylprostaglandin E2 </e1>  ( <e2> dmPGE2 </e2> )-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. 
false	Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing  <e1> 99mTc-MDP </e1>  as the  <e2> radiopharmaceutical </e2>  was carried out in 22 patients. 
false	This article looks at five commonly used immunosuppressive drugs in turn ( <e1> corticosteroids </e1> , cyclosporin,  <e2> azathioprine </e2> , methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine,  <e1> methotrexate </e1> ,  <e2> cyclophosphamide </e2> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used  <e1> immunosuppressive drugs </e1>  in turn (corticosteroids,  <e2> cyclosporin </e2> , azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol,  <e1> methanol </e1> , higher alcohols and  <e2> acetaldehyde </e2>  in the same proportions as those found in most common distilled and fermented alcoholic beverages; 
false	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  <e1> ethanol </e1> , methanol, higher  <e2> alcohols </e2>  and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 
false	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen  <e1> 4-hydroxytamoxifen </e1>  ( <e2> TAM </e2> ), which also induces apoptosis in MCF-7 cells. 
false	In the experiments reported here, we examined the interactions between  <e1> 1,25(OH)2D3 </e1>  and the antiestrogen 4-hydroxytamoxifen ( <e2> TAM </e2> ), which also induces apoptosis in MCF-7 cells. 
false	1,25-Dihydroxycholecalciferol D3 ( <e1> 1,25(OH)2D3 </e1> ), the active metabolite of  <e2> vitamin D </e2> , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 
false	We investigated the effects of adenosine receptor antagonists, caffeine,  <e1> theophylline </e1> , 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine ( <e2> DPCPX </e2> ), in a light/dark test in mice. 
false	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by  <e1> CGS 21680 </e1>  nor by  <e2> CPA </e2> . 
false	We investigated the effects of adenosine receptor antagonists,  <e1> caffeine </e1> , theophylline,  <e2> 8-phenyltheophylline </e2> , and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 
false	The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by  <e1> N6-cyclopentyladenosine </e1>  ( <e2> CPA </e2> ), an A1-selective agonist. 
false	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the  <e1> antiestrogen </e1>  4-hydroxytamoxifen ( <e2> TAM </e2> ), which also induces apoptosis in MCF-7 cells. 
false	The anxiogenic effects of theophylline were reduced by pretreatment with  <e1> CGS 21680 </e1> , an A2-selective agonist, but not by N6-cyclopentyladenosine ( <e2> CPA </e2> ), an A1-selective agonist. 
false	We investigated the effects of adenosine receptor antagonists,  <e1> caffeine </e1> , theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine ( <e2> DPCPX </e2> ), in a light/dark test in mice. 
false	In dogs,  <e1> cimetidine </e1>  unchanged the secretion of  <e2> cardiotrast </e2> , a test agent for anionic transport. 
false	[The effect of  <e1> cimetidine </e1>  on the renal excretion of  <e2> verografin </e2>  and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 
false	[The effect of  <e1> cimetidine </e1>  on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c <e2> imetidine  </e2> in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v <e1> erografine  </e1> and i <e2> odamide  </e2> excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of  <e1> verografin </e1>  and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v <e2> erografine  </e2> and iodamide excretion in chronic canine experiments. 
false	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of  <e1> vitamin B6 </e1> , physiological doses of  <e2> vitamin D </e2>  and of selenium. 
false	Two different types of therapy with magnesium are used: physiological oral  <e1> magnesium </e1>  supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the  <e2> magnesium </e2>  intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e1> magnesium </e1>  deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of  <e2> magnesium </e2>  status which requires more or less specific regulation of its causal dysregulation. 
false	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of  <e1> vitamin B6 </e1> , physiological doses of vitamin D and of  <e2> selenium </e2> . 
false	Specific and aspecific treatments of  <e1> magnesium </e1>  depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of  <e2> vitamin B6 </e2> , physiological doses of vitamin D and of selenium. 
false	Two different types of therapy with magnesium are used: physiological oral  <e1> magnesium </e1>  supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic  <e2> magnesium </e2>  overload. 
false	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates  <e1> magnesium </e1>  deficiencies by simply normalizing the  <e2> magnesium </e2>  intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and  <e1> magnesium </e1>  depletion related to a dysregulation of the control mechanisms of  <e2> magnesium </e2>  status which requires more or less specific regulation of its causal dysregulation. 
false	Two different types of therapy with magnesium are used: physiological oral  <e1> magnesium </e1>  supplementation which is totally atoxic since it palliates  <e2> magnesium </e2>  deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates  <e1> magnesium </e1>  deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic  <e2> magnesium </e2>  overload. 
false	The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and  <e1> glutamate </e1>  (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of  <e2> glutamate </e2>  alone. 
effect	Interaction between  <e1> glycine </e1>  and  <e2> glutamate </e2>  in the development of spontaneous motility in chick embryos.
false	Compromised  <e1> norepinephrine </e1>  uptake-1 in functional class IV cannot be further increased by cocaine and  <e2> desipramine </e2> . 
false	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and a <e1> ngiotensin 2  </e1> on p <e2> entagastrin- </e2>  and histamine-induced gastric acid secretion. 
false	It was established that both angiotensins inhibited gastric acid secretion stimulated by  <e1> pentagastrin </e1>  but not by  <e2> histamine </e2> . 
false	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and a <e1> ngiotensin 2  </e1> on pentagastrin- and h <e2> istamine- </e2> induced gastric acid secretion. 
false	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of a <e1> ngiotensin 1  </e1> and angiotensin 2 on p <e2> entagastrin- </e2>  and histamine-induced gastric acid secretion. 
effect	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for  <e1> atracurium </e1>  plus  <e2> gentamycin </e2> . 
false	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for  <e1> atracurium </e1>  alone and 11.5 +/- 2.7 min for atracurium plus  <e2> gentamycin </e2>  (P = 0.03). 
mechanism	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume  <e1> alcohol </e1>  and  <e2> 3-hydroxy-1,4-benzodiazepine </e2>  on a regular basis. 
false	The  <e1> benzodiazepines </e1>  are a family of anxiolytic and  <e2> hypnotic drugs </e2> . 
false	Weekly intramuscular  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 
effect	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys were significantly affected. 
false	In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist,  <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> . 
false	Weekly intramuscular  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle). 
false	Weekly intramuscular  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2>  versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 
false	In  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys. 
false	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of  <e1> panobinostat </e1>  (LBH589), an orally active  <e2> histone deacetylase inhibitor </e2> .
false	After 21 weeks of  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys were significantly affected. 
false	The response of  <e1> moxifloxacin </e1>  and  <e2> lomefloxacin </e2>  after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. 
mechanism	Moxifloxacin and  <e1> Lomefloxacin </e1>  reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and  <e2> multi-minerals </e2>  in neutral media. 
false	Interaction study of  <e1> moxifloxacin </e1>  and  <e2> lomefloxacin </e2>  with co-administered drugs.
false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil,  <e1> erythromycin </e1>  and  <e2> multi minerals </e2> . 
false	Being moxifloxacin and lomefloxacin  <e1> fluoroquinolones </e1>  the interaction study of was carried out with  <e2> sucralfate </e2> , gelusil, erythromycin and multi minerals. 
false	This study evaluated the effect of a potent CYP3A inhibitor,  <e1> ketoconazole </e1> , on the pharmacokinetics and safety of  <e2> panobinostat </e2> .
mechanism	Moxifloxacin and  <e1> Lomefloxacin </e1>  reacts faster with sucralfate and gelusil in acidic media whereas with  <e2> erythromycin </e2>  in basic media and multi-minerals in neutral media. 
false	Moxifloxacin and  <e1> lomefloxacin </e1>  are  <e2> fluoroquinolone antibiotics </e2>  used in treating urinary and respiratory tract infections. 
false	The ratio of  <e1> norketamine </e1>  AUC(0-   ) to  <e2> ketamine </e2>  AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 
false	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral  <e1> ticlopidine </e1>  (250 mg twice daily),  <e2> itraconazole </e2>  (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 
false	Exposure to oral S-ketamine is unaffected by  <e1> itraconazole </e1>  but greatly increased by  <e2> ticlopidine </e2> .
false	Being moxifloxacin and lomefloxacin  <e1> fluoroquinolones </e1>  the interaction study of was carried out with sucralfate, gelusil, erythromycin and  <e2> multi minerals </e2> . 
false	 <e1> Ticlopidine </e1>  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to  <e2> S-ketamine </e2> . 
false	We also found that Bcl-2 was overexpressed in  <e1> DZNep </e1>  insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  <e2> DZNep </e2>  insensitive MM cells. 
false	The  <e1> 3-Deazaneplanocin A </e1>  ( <e2> DZNep </e2> ), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. 
false	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor  <e1> ticlopidine </e1>  and the CYP3A inhibitor  <e2> itraconazole </e2> . 
effect	 <e1> Implanon </e1>    failure in an HIV-positive woman on  <e2> antiretroviral </e2>  therapy resulting in two ectopic pregnancies.
false	Warfarin users who initiated citalopram,  <e1> fluoxetine </e1> , paroxetine, amitriptyline, or  <e2> mirtazapine </e2>  had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users who initiated  <e1> citalopram </e1> , fluoxetine, paroxetine,  <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
effect	 <e1> Warfarin </e1>  users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or  <e2> mirtazapine </e2>  had an increased risk of hospitalization for gastrointestinal bleeding. 
false	In total, 430,455  <e1> warfarin </e1>  users contributed 407,370 person-years of  <e2> warfarin </e2>  use. 
false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of  <e1> citalopram </e1>  (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]),  <e2> amitriptyline </e2>  (OR   =   1.47 [95% CI, 1.02-2.11]). 
effect	Also  <e1> mirtazapine </e1> , which is not believed to interact with  <e2> warfarin </e2> , increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). 
false	With respect to toxicity, the order of CYP inhibitor effectiveness was  <e1> ABT </e1> >diethyldithiocarbamate~tranylcypromine> <e2> ketoconazole </e2> . 
false	Furafylline and  <e1> sulfaphenazole </e1>  had no effect, while quinidine appeared to augment  <e2> precocene I </e2>  toxicity. 
effect	Furafylline and sulfaphenazole had no effect, while  <e1> quinidine </e1>  appeared to augment  <e2> precocene I </e2>  toxicity. 
false	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT> <e1> diethyldithiocarbamate </e1> ~tranylcypromine> <e2> ketoconazole </e2> . 
false	 <e1> Furafylline </e1>  and sulfaphenazole had no effect, while quinidine appeared to augment  <e2> precocene I </e2>  toxicity. 
false	To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of  <e1> adeno-associated virus-2 </e1>  ( <e2> AAV2 </e2> ).
false	 <e1> AAV2 </e1>  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  <e2> collagenase </e2> , hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 
false	The incubations were performed in the absence and presence of the non-specific CYP inhibitor,  <e1> 1-aminobenzotriazole </e1>  ( <e2> ABT </e2> ) and isoform-specific inhibitors. 
effect	 <e1> ABT </e1>  decreased the toxicity of  <e2> precocene I </e2> , increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. 
false	 <e1> AAV2 </e1>  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or  <e2> chondroitin ABC lyase </e2> . 
false	 <e1> Hyaluronan lyase </e1>  had a limited effect and  <e2> collagenase </e2>  was ineffective. 
false	 <e1> AAV2 </e1>  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase,  <e2> hyaluronan lyase </e2> , heparinase III, or chondroitin ABC lyase. 
false	Depression does not always require  <e1> antidepressant drug </e1>  therapy, and  <e2> antidepressants </e2>  have no proven preventive impact on hot flushes linked to the menopause. 
false	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as  <e1> paroxetine </e1>  and  <e2> fluoxetine </e2> . 
advise	If in certain cases, an  <e1> antidepressant </e1>  is considered necessary, it may be advisable to replace  <e2> tamoxifen </e2>  with anastrozole.
false	Rats treated with neonatal quinpirole enhanced time spent in the  <e1> amphetamine </e1> -paired context compared with quinpirole-free controls conditioned with  <e2> amphetamine </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 
false	EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose  <e1> ketamine </e1>  was added to  <e2> propofol </e2> . 
false	In female rats, neonatal quinpirole treatment enhanced  <e1> amphetamine </e1>  locomotor sensitization compared with  <e2> quinpirole </e2> -free controls sensitized to amphetamine. 
false	The objective was to analyze the effects of neonatal  <e1> quinpirole </e1>  treatment on effects of  <e2> amphetamine </e2>  in adolescent rats using locomotor sensitization and conditioned place preference procedures. 
false	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving  <e1> cyclosporine </e1>  than in those receiving  <e2> tacrolimus </e2> , indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 
false	In vitro studies have identified  <e1> cyclosporine </e1>  and  <e2> tacrolimus </e2>  as CYP3A inhibitors. 
false	Systemic and apparent oral  <e1> midazolam </e1>  clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched  <e2> tacrolimus </e2> -treated patients (n = 20). 
false	The latter displayed  <e1> midazolam </e1>  clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a  <e2> calcineurin inhibitor </e2> -free regimen (n = 6). 
false	We found antagonism between  <e1> celecoxib </e1>  and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between  <e2> celecoxib </e2>  and doxorubicin in all cell lines except for two combinations in HCT116 cells. 
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU,  <e1> cisplatin </e1> , doxorubicin and  <e2> etoposide </e2>    celecoxib following different incubation schedules were analyzed.
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  <e1> 5-FU </e1> , cisplatin, doxorubicin and  <e2> etoposide </e2>    celecoxib following different incubation schedules were analyzed.
false	The drug interaction between  <e1> proton pump inhibitors </e1>  and  <e2> clopidogrel </e2>  has been the subject of much study in recent years. 
false	Concomitant use of omeprazole and  <e1> clopidogrel </e1>  was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by  <e2> omeprazole </e2>  of CYP2C19, a cytochrome P450 (CYP) enzyme. 
false	The susceptibility results for  <e1> minocycline </e1>  and  <e2> fosfomycin </e2>  were interpreted according to the most relevant criteria. 
false	These results, if confirmed in-vivo, indicate that  <e1> celecoxib </e1>  is not a suitable chemosensitizer for breast cancer or with  <e2> doxorubicin </e2>  for other cancers. 
false	Questioning revealed the child was taking  <e1> Infacol </e1>  drops before feeds while on  <e2> levothyroxine </e2> . 
false	We evaluated the effects of  <e1> calcium </e1>  doses between 200 and 1500 mg on absorption of 5 mg  <e2> nonheme iron </e2>  (as ferrous sulfate). 
false	 <e1> Calcium </e1>  was administered as calcium chloride in all studies and  <e2> minerals </e2>  were ingested on an empty stomach. 
mechanism	 <e1> Calcium </e1>  doses   1000 mg diminished  <e2> nonheme iron </e2>  absorption by an average of 49.6%.
false	Calcium was administered as  <e1> calcium chloride </e1>  in all studies and  <e2> minerals </e2>  were ingested on an empty stomach. 
false	Calcium is the only known component in the diet that may affect absorption of both nonheme and  <e1> heme i <e2> ron </e1>  </e2> . 
false	However, the evidence for a  <e1> calcium </e1>  effect on iron absorption mainly comes from studies that did not isolate the effect of  <e2> calcium </e2>  from that of other dietary components, because it was detected in single-meal studies. 
effect	The molecular basis of this synergism is that the signaling pathways that were initially activated by  <e1> docetaxel </e1>  exposure were efficiently suppressed by the subsequent exposure to  <e2> sunitinib </e2> . 
false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  <e1> docetaxel </e1>  followed by sunitinib is superior to sunitinib followed by  <e2> docetaxel </e2>  and concurrent administration.
false	NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either  <e1> sunitinib </e1>  or  <e2> docetaxel </e2>  or both based on various sequential administrations. 
effect	Synergism was also noted when  <e1> methylglyoxal </e1>  was combined with carbenicillin and  <e2> amikacin </e2> .
false	This study was aimed to investigate the efficacy of single use of  <e1> sunitinib </e1>  and that of concurrent or sequential administration of  <e2> sunitinib </e2>  and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.
false	Synergism was also noted when methylglyoxal was combined with  <e1> carbenicillin </e1>  and  <e2> amikacin </e2> .
false	 <e1> Sunitinib </e1>  exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas  <e2> docetaxel </e2>  arrested at S phase. 
false	and/or  <e1> antibiotic drug </e1>  doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin  <e2> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e2>  (MPTP) (4 x 20 mg/kg, i. p.) 
false	[Influence of  <e1> hemantane </e1>  and  <e2> doxycycline </e2>  on MPTP-evoked behavior violations in C57BL/6 mice].
false	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib +  <e1> paclitaxel </e1>  vs  <e2> paclitaxel </e2> : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
effect	HEY cells treated with  <e1> dasatinib </e1>  plus  <e2> paclitaxel </e2>  formed fewer colonies than did cells treated with either agent alone. 
false	 <e1> dasatinib </e1>  +  <e2> paclitaxel </e2>  vs. 
false	Treatment of HEY xenograft-bearing mice with  <e1> dasatinib </e1>  plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  <e2> dasatinib </e2>  + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Treatment of HEY xenograft-bearing mice with dasatinib plus  <e1> paclitaxel </e1>  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs  <e2> paclitaxel </e2> : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Phase I trial of lenalidomide and  <e1> CCI-779 </e1>  in patients with relapsed multiple myeloma: evidence for lenalidomide- <e2> CCI-779 </e2>  interaction via P-glycoprotein.
false	The objective of this study was to evaluate the effect of oral administration of  <e1> ginseng stem-and-leaf saponins </e1>  (GSLS) on the humoral immune responses of chickens to inactivated ND and  <e2> AI </e2>  vaccines. 
false	The objective of this study was to evaluate the effect of oral administration of  <e1> ginseng stem-and-leaf saponins </e1>  (GSLS) on the humoral immune responses of chickens to inactivated ND and AI  <e2> vaccines </e2> . 
false	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins ( <e1> GSLS </e1> ) on the humoral immune responses of chickens to inactivated ND and  <e2> AI </e2>  vaccines. 
false	We evaluated mechanisms of interaction between the alkyating agent dacarbazine ( <e1> DTIC </e1> ) and the pro-oxidant,  <e2> imexon </e2> , in the human A375 melanoma cell line.
false	 <e1> Lapatinib </e1>  may have the potential to convert Herceptin-refractory to  <e2> Herceptin </e2> -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
false	Although it was previously reported that  <e1> lapatinib </e1>  combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with  <e2> Herceptin </e2> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
effect	 <e1> Imexon </e1>  and  <e2> dacarbazine </e2>  show additive effects in vitro but not in vivo in human A375 melanoma cells.
false	We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of  <e1> CRM197 </e1>  on these cells alone or in combination with  <e2> anticancer agent </e2> . 
false	Although it was previously reported that lapatinib combined with  <e1> Herceptin </e1>  improved the progression-free survival rate compared with  <e2> lapatinib </e2>  alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
false	We concluded that the combined administration of dexmedetomidine with  <e1> ephedrine </e1>  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  <e2> dexmedetomidine </e2>  as an analgesic in humans.
false	saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and  <e1> ephedrine </e1>  (10   mg/kg) +  <e2> dexmedetomidine </e2>  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 
effect	CRM197 induced apoptosis, and furthermore, the combination of  <e1> CRM197 </e1>  plus  <e2> doxorubicin </e2>  enhanced cytotoxicity in a T-ALL cell line. 
false	But the use of fixed combination amlodipine/ <e1> valsartan </e1>  compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of  <e2> antihypertensive drugs </e2>  (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 
effect	But the use of fixed combination  <e1> amlodipine </e1> / <e2> valsartan </e2>  compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 
false	Efficacy and tolerability of fixed  <e1> amlodipine </e1> / <e2> valsartan </e2>  combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. 
false	It will compete with clopidogrel (Plavix) and  <e1> prasugrel </e1>  ( <e2> Effient </e2> ) for such use. 
false	The FDA has approved ticagrelor ( <e1> Brilinta </e1> -AstraZeneca), an oral  <e2> antiplatelet drug </e2> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 
false	 <e1> Ticagrelor </e1>  (Brilinta)--better than  <e2> clopidogrel </e2>  (Plavix)
false	It will compete with clopidogrel ( <e1> Plavix </e1> ) and  <e2> prasugrel </e2>  (Effient) for such use. 
effect	In the present study  <e1> piperine </e1>  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  <e2> ibuprofen </e2>  evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 
false	The synergistic antinociception activity of ibuprofen when administered with  <e1> piperine </e1>  can be attributed to increased plasma concentration of  <e2> ibuprofen </e2> . 
false	In the present study  <e1> piperine </e1>  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with  <e2> ibuprofen </e2> . 
